PTHS news

Pelthos Therapeutics Inc. filed a plan to replace its 2023 plan and provide equity awards. Adopting such plans is a routine corporate governance action that can impact long-term employee incentives and shareholder value.

Pelthos Therapeutics announced CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, with one-on-one investor meetings available. The presentation provides investors opportunity to engage with the commercial-stage biopharmaceutical company focused on cutaneous …

Pelthos Therapeutics Inc. terminated the employment of Francis Knuettel II effective April 10, 2026, providing $430,000 in separation pay plus 12 months of base salary. The executive departure represents a leadership change at the biopharmaceutical company.